EconomyNovartis cuts medium-term growth target; shares fall
Swiss drugmaker Novartis set an annual sales growth target of 5% through 2031, at the low end of its previous five-year guidance. Approaching patent expiries and a run of late-stage trial setbacks are adding pressure on its blockbuster drugs.
Novartis cuts medium-term growth target; shares fall
